Irhythm Holdings, Inc. · NASDAQ:IRTC
Irhythm — Q1 2026 Earnings Presentation
19 slides from Irhythm's earnings presentation, Apr 30, 2026
Slide 1: iRhythm Holdings First Quarter 2026 Results
iRhythm Holdings First Quarter 2026 Results April 30, 2026 © 2026 iRhythm Holdings, Inc. 1
Slide 2: Cautionary statement re forward-looking statements, non-GAAP measures and other matters
Cautionary statement re forward-looking statements, non-GAAP measures and other matters Certain data in this presentation was obtained from various external sources, and neither “iRhythm Holdings, Inc. You should not rely upon forward-looking statements as predictions of future events. Although we b
Slide 3: Addressing major challenges and opportunities in healthcare
Addressing major challenges and opportunities in healthcare IRHY THM’S IMPACT ADDRESSING UNMET MARKET CATALYSTS GROWING ACCESS NEED GAP 20 years advancing cardiac Heart rhythm problems Aging population, consumer 46.3% of all U.S. counties – diagnostics and innovating are among the most arrhythmia aw
Slide 4: 27+ million $199.4 million 2.6 million
27+ million $199.4 million Potential patients in the United First quarter 2026 revenue, States who could benefit from a 25.7% increase year-over-year ambulatory cardiac monitoring* 2.6 million 3.2 million tests Patient reports posted annually Target market opportunity across prioritized EU and APAC
Slide 5: ACM market is evolving with runway for durable growth
ACM market is evolving with runway for durable growth TREMENDOUS MARKET EXPANSION POTENTIAL AHEAD MARKET LEADERSHIP IN LTCM : 72% market share in LTCM (of 3.5 million tests in US today growing high teens % YOY) with ~ 27 million undiagnosed US patients at elevated risk SHORT DURATION MONITORS YET TO
Slide 6: Primary care adoption key to accessing expansive TAM
Primary care adoption key to accessing expansive TAM IRHY THM UNIQUELY POSITIONED TOTAL MARKET CLAIMS BY APPROACHING PRIMARY CARE VIA TO WIN IN PRIMARY CARE MODALIT Y & SPECIALT Y T WO-PRONGED STRATEGY MCT ✓ Market leader in LTCM, the preferred modality EVENT Land-and-expand within ✓ Rule-in/rule-ou
Slide 7: Next-gen MCT designed to extend our category leadership
Next-gen MCT designed to extend our category leadership Zio AT® Zio MCT** (Not yet FDA cleared, 510(k) submitted 3Q25) Improved form factor Device form factor Legacy patch technology • Same platform as Zio monitor • Better adhesion and battery Wear duration Up to 14 days Up to 21 days Auto-detects a
Slide 8: Significant runway in international expansion
Significant runway in international expansion PRIORITIZED EU COUNTRIES Switzerland, Spain, Austria, UNITED KINGDOM and the Netherlands JAPAN Early commercialization Early commercialization Early commercialization 700,000 900,000 1,600,000 Ambulatory cardiac monitoring Ambulatory cardiac monitoring A
Slide 9: 1Q26 milestones reflective of execution and momentum
1Q26 milestones reflective of execution and momentum ACCELERATING BRINGING GENERATING MOMENTUM IN PROVIDING A INNOVATIVE PEER-REVIEWED EXECUTING WITH COMMERCIAL WINNING CUSTOMER PRODUCTS TO CLINICAL EXPANDING MARKET DISCIPLINE & BUSINESS EXPERIENCE MARKET EVIDENCE ACCESS EFFICIENCY $199.4 million re
Slide 10: First quarter 2026 financial performance
First quarter 2026 financial performance GLOBAL NET REVENUE GROSS PROFIT MARGIN (USD, MILLIONS) $208.9 $199.4 $192.9 71.2% 71.1% 70.9% 70.9% $186.7 $158.7 68.8% 1Q2025 2Q2025 3Q2025 4Q2025 1Q2026 1Q2025 2Q2025 3Q2025 4Q2025 1Q2026 ADJUSTED OPERATING EXPENSES * ADJUSTED EBITDA MARGIN * (USD, MILLIONS
Slide 11: 2026 annual revenue and profitability guidance
2026 annual revenue and profitability guidance PRIOR GUIDANCE Adjusted EBITDA Net revenue margin $870 - $880 million UPDATED GUIDANCE 11.5 – 12.5% of revenue* Adjusted EBITDA Net revenue margin $875 - $885 million 12 – 13% of revenue* *Adjusted EBITDA excludes non-cash operating charges for stock-ba
Slide 12: 2026 outlook balances growth across near-term opportunities
2026 outlook balances growth across near-term opportunities U.S. CORE COMMERCIAL BUSINESS • Further expansion into PCP channel GLOBAL NET REVENUE (USD, MILLIONS) • New technologies (e.g., PFA) expand monitoring $875 – • MCT market expansion with continued innovation $885 $747.1 $591.8 INTERNATIONAL
Slide 13: Addressing the future focus of healthcare
Addressing Expanding core the future focus & unlocking of healthcare adjacent markets Growing revenue Driving through global market meaningful expansion improvements in financial profile
Slide 14: Appendix
Appendix
Slide 15: Reconciliation of net income (loss) to adjusted EBITDA
Reconciliation of net income (loss) to adjusted EBITDA Adjusted EBITDA is a non-GAAP financial measure and is presented for supplemental informational purposes only and should not be considered as an alternative or substitute to financial information presented in accordance with GAAP. Adjusted EBITD
Slide 16: Reconciliation of GAAP to non-GAAP financial information
Reconciliation of GAAP to non-GAAP financial information Adjusted EBITDA, adjusted net income (loss), adjusted net income (loss) per share, adjusted operating expenses, and free cash flow are non-GAAP financial measures and are presented for supplemental informational purposes only and should not be
Slide 17: Reconciliation of GAAP to non-GAAP financial information
Reconciliation of GAAP to non-GAAP financial information (USD, THOUSANDS) THREE MONTHS ENDED MARCH 31, ADJUSTED NET LOSS RECONCILIATION* 2026 2025 Net loss, as reported1 $ (13,933) $ (30,700) Business transformation costs 346 503 Intellectual property litigation costs2 3,689 832 Changes in fair valu
Slide 18: Reconciliation of GAAP to non-GAAP financial information
Reconciliation of GAAP to non-GAAP financial information (USD, THOUSANDS) THREE MONTHS ENDED MARCH 31, ADJUSTED OPERATING EXPENSES RECONCILIATION* 2026 2025 Operating expenses, as reported $ 157,538 $ 141,772 Business transformation costs (346) (503) Intellectual property litigation costs1 (3,689) (
Slide 19: Slide(s) sources
SLIDE(S) SOURCES ‘Addressing major challenges • Ward et al. Prevalence and health care expenditures among Medicare beneficiaries aged 65 years and over with heart conditions. Medicare Current Beneficiary and opportunities in Survey, 2017. (Prevalence of self-reported heart conditions.) American Coll